Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003017 · ClinicalTrials.gov registry record · Phase 2
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
A Phase 2 study of Cervical Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Study locations
NCT00003017: Completed Phase 2 study of Cervical Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00003017 is a Phase 2 study of Cervical Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003017, a Phase 2 study of Cervical Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9
- Study locations
Study Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells in the cervix. PURPOSE: Phase II trial to study the effectiveness of interleukin-12 in treating patients who have advanced or recurrent cancer of the cervix.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interleukin-12
Study Locations (9)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
- University of Rochester Cancer Center - Rochester
- Albert Einstein Comprehensive Cancer Center - The Bronx
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- CCOP - Northern New Jersey - Hackensack
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Tennessee
- Vanderbilt Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00003017 record still lists
NCT00003017 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which recombinant interleukin-12 is the first listed.
NCT00003017 lists 9 locations in 5 states (New York, New Jersey, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00003017 about?
NCT00003017 is a clinical study titled "Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix". RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells in the cervix. PURPOSE: Phase II trial to study the effectiveness of interleukin-12 in treating patients who have advanced or recurrent cancer of t...
What is the current status of trial NCT00003017?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-07. Estimated completion is 2005-08.
What conditions does trial NCT00003017 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00003017?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003017?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003017 being conducted?
This trial has 9 study locations across Massachusetts, New Jersey, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia